Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin plus cytarabine versus placebo plus cytarabine in relapsed or refractory acute myeloid leukemia
NL-OMON47508Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Idasanutlin + cytarabine with Placebo + cytarabine (2 arms). Primary endpoint: Overall survival. Started Nov 2016; status: active, not recruiting.
02
Drugs
idasanutlincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON47508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47508.